Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer
577 Biopsy-associated tumor regression in late relapsed DLBCL after tandem CD20-CD19 CAR-T cell therapy
- 12Agenus, Lexington, MA, USA
- 2Miltenyi Biomedicine, Boston, MA, USA
- 3Oregon Health & Science University, Portland, OR, USA
Related
- Biopsy-proven Systemic Lupus Erythematosus and Antineutrophil Cytoplasmic Antibody-associated Vasculitis Overlap Syndrome Developed during Propylthiouracil Therapy: A Case-based Review
- Baseline Spleen Volume is Independently Associated With Survival After CD19-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
- Pretreatment Prognostic Nutritional Index Is Associated with Treatment Response and Survival in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Receiving CAR-T Cell Therapy
- Purpureocillium lilacinum Fungemia Masquerading as an Unidentified Yeast in a Heavily Immunosuppressed Patient With Relapsed Multiple Myeloma and Therapy-Related Mixed-Phenotype Acute Leukemia: A Case Report
- 200 Preclinical evaluation of a tandem PD-L1/EphA2 CAR-T cell therapy in multiple solid tumor models
BibTeX
@article{nallewar2026biopsyassociated,
title = {{577 Biopsy-associated tumor regression in late relapsed DLBCL after tandem CD20-CD19 CAR-T cell therapy}},
author = {Madhavi Nallewar and Kevin M Christmas and Levanto G Schachter and Richard T Maziarz},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
month = nov,
doi = {10.1136/jitc-2026-sitc2026.0577},
url = {https://doi.org/10.1136/jitc-2026-sitc2026.0577},
note = {CC BY},
}
RIS
TY - JOUR
TI - 577 Biopsy-associated tumor regression in late relapsed DLBCL after tandem CD20-CD19 CAR-T cell therapy
AU - Madhavi Nallewar
AU - Kevin M Christmas
AU - Levanto G Schachter
AU - Richard T Maziarz
PY - 2026
DA - 2026/11/07
JO - Journal for ImmunoTherapy of Cancer
DO - 10.1136/jitc-2026-sitc2026.0577
UR - https://doi.org/10.1136/jitc-2026-sitc2026.0577
SN - 2051-1426
ER -